Secondary
Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders.
Symbol
FATE
Last Closing Price
$4.43
Effective Date
December 13, 2017
Underwriters
Leerink Partners, Piper Jaffray
To view the prospectus for Fate Therapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277